Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923805 | 0.86 | TBXA2R (0.49) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6928480 | 0.85 | MAPT (0.56) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6930116 | 0.85 | HSPB1 (0.49) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL21177892 | 0.83 | HSPB1 (0.77) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6536062 | 0.82 | ALDH1A1 (0.49) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL31287841 | 0.82 | HSPB1 (0.82) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL274702 | 0.81 | LMNA (0.52) | HSPB1MAPTALDH1A1KMT2AERN1 | |
| SCHEMBL7111696 | 0.80 | PTGS2 (0.51) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL275261 | 0.80 | PDE7A (0.51) | HSPB1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL29227165 | 0.80 | CYP19A1 (0.56) | HSPB1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-4118572-A | CNS DEPRESSANTS, NEUROLEPTIC AGENTS, SCHIZOPHRENIA, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4105664-A | Dibenz[b,f]oxepin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4100173-A | DEPRESSANTS, SCHIZOPHRENIA, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-07-11 | — | — | US | disclosed |
| US-4091023-A | ANTISCHIZOPHRENIA AGENTS, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4032525-A | CNS DEPRESSANTS, NEUROLEPTICS | HOFFMANN-LA ROCHE INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | HDAC8, HDAC5, HDAC7 | HSPB1 865/4885MAPT 2192/4885ALDH1A1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.